Italia markets closed

Active Biotech AB (publ) (0GQU.L)

LSE - LSE Prezzo differito. Valuta in SEK.
Aggiungi a portafoglio
2,8500+1,3420 (+88,99%)
Alla chiusura: 01:06PM GMT
Schermo intero
Chiusura precedente1,5080
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno1,5040 - 1,5040
Intervallo di 52 settimane1,5040 - 1,5040
Media VolumeN/D
Beta (5 anni mensile)0,77
Rapporto PE (ttm)N/D
EPS (ttm)-0,2140
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Active Biotech Appoints Erik Vahtola as Chief Medical Officer

    Lund, January 4, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer (CMO), effective January 1, 2022. He will join the executive management team and be responsible for the development of the company´s clinical project portfolio within solid and hematological cancers, and inflammatory eye disorders. Dr. Vahtola has more than 10 years of experience altogether from regulatory authority and pharma industry positions

  • GlobeNewswire

    Preclinical tasquinimod data presented at ASH 2021 available on Active Biotech’s website

    Lund, December 15, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule immunomodulator, are now available on the company’s website. The data were presented at two poster presentations at the 63rd ASH Annual Meeting & Exposition in Atlanta, Georgia. The results presented are part of Active Biotech’s program to address the unmet medical needs to treat hematological malignances, including multiple myeloma. Currentl

  • GlobeNewswire

    Active Biotech's nomination committee appointed

    In accordance with a decision made by the Annual General Meeting held on May 19, 2021, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2021, and the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights. Based on the above, the Nomin